MV Chandrakanth, Academic Head and Medical Oncologist at Narayana Health, shared on X:
“PE-PE / ESMO 2026 / LBA88
Can pembrolizumab delay relapse after treating all visible metastases in oligometastatic RCC?
The randomized Phase II PE-PE trial suggests YES!
- Median RFS: 25.4 vs 11.0 months
- HR 0.47 / p = 0.024
- 53% lower hazard of relapse or death
Interestingly, 94% of progression events were distant, highlighting the importance of occult systemic disease despite definitive local treatment.
OS remains immature. Toxicity requires consideration.
The takeaway: Perioperative pembrolizumab + metastasis-directed therapy significantly prolonged RFS in selected oligometastatic clear-cell RCC.
Promising Phase II evidence – not yet definitive. ”
You can also read:
Key Updates in GU Oncology From ESMO 2026
